XML 41 R31.htm IDEA: XBRL DOCUMENT v3.19.1
Fair value measurement - BMS warrants - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Feb. 01, 2019
Mar. 31, 2019
Apr. 06, 2015
Collaboration arrangements      
Proceeds from exercise of warrants   $ 500  
BMS Warrants      
Collaboration arrangements      
Exercise price in respect of each warrant   $ 48.92 $ 33.84
Number of trading days used to calculate Volume Weighted Average Price ("VWAP")   20 days  
Number of days prior to purchase or exercise used to calculate Volume Weighted Average Price ("VWAP")   5 days  
Compounded annual growth rate used to determine fair value of exercise price   10.00%  
Increase in volatility rate   10.00%  
Volatility rate   85.00%  
BMS Warrants | Minimum      
Collaboration arrangements      
Period in which the exercise of warrants is expected to occur after balance sheet date (in years)   2 years  
BMS Warrants | Maximum      
Collaboration arrangements      
Period in which the exercise of warrants is expected to occur after balance sheet date (in years)   4 years  
uniQure N.V. | Bristol Myers Squibb | First Six New Targets Or Designation Of Sixth Target      
Collaboration arrangements      
Ownership percentage required per agreement   14.90%  
uniQure N.V. | Bristol Myers Squibb | First Nine New Targets Or Designation Of Ninth Target      
Collaboration arrangements      
Ownership percentage required per agreement   19.90%  
BMS arrangement | Bristol Myers Squibb | Hercules Warrants [Member]      
Collaboration arrangements      
Number of shares issued for exercise of warrants 37,175    
Issue price per share $ 34.25    
Proceeds from exercise of warrants $ 500